Virtual screening of novel compounds as potential ER-alpha inhibitors

Majority of breast cancers diagnosed today are estrogen receptor (ER)-positive, however, progesterone receptor-positive (PR-positive) is also responsible for breast cancer. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. Nearly 1...

Descripción completa

Detalles Bibliográficos
Autores principales: TilakVijay, Jakkanaboina, Vivek Babu, Kandimalla, Uma, Addepally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589477/
https://www.ncbi.nlm.nih.gov/pubmed/31249434
http://dx.doi.org/10.6026/97320630015321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589477/
https://www.ncbi.nlm.nih.gov/pubmed/31249434
http://dx.doi.org/10.6026/97320630015321

Ejemplares similares